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Abstract
Identification of individuals at high risk of dementia has usually focused attention on the clinical concept of mild cognitive 
impairment (MCI), which captures an intermediate state between normal cognitive ageing and dementia. In many countries 
age specific risk of dementia has declined, but whether this is also the case for subclinical cognitive impairment is unknown. 
This has important implications for prevention, planning and policy. Here we describe subclinical cognitive impairment and 
mild dementia prevalence changes, in the UK, over 2 decades. The Cognitive Function and Ageing Studies have examined 
the full spectrum of cognition, from normal to dementia, in representative populations of people aged ≥ 65 years in the UK 
over the last 2 decades 7635 participants were interviewed in CFAS I in Cambridgeshire, Newcastle, and Nottingham in 
1991, with 1457 being diagnostically assessed. In the same geographical areas, the CFAS II investigators interviewed 7796 
individuals in 2011. Using established criteria, the population was categorised into seven groups: no cognitive impairment, 
Mild cognitive Impairment (defined using consensus criteria), other cognitive impairment no dementia without functional 
impairment, OCIND with functional impairment, cognitive impairment (MMSE < 24 and no functional impairment), mild 
dementia (MMSE < 24 with functional impairment, not captured by CFAS dementia criteria), and CFAS dementia criteria. 
Multinomial logistic regression, adjusted for age and sex, was used to estimate the prevalence of impairment in both studies. 
Results were standardized to the age-sex specific UK and global population. There is a clear increase in the prevalence of 
other cognitive Impairment no Dementia (without functional impairment), with the purer MCI remaining stable. In the UK, 
mild dementia is estimated to fall from 520,704 cases (5.7%, 95% CI 3.8, 8.1) in 1991 to 315,142 (3.0%, 95% CI 2.4, 3.8) in 
2011, cognitive impairment, has fallen from 1,225,984 (13.5%, 95% CI 10.1, 17.5) to 654,436 (6.3%, 95% CI 5.4, 7.3) cases. 
Using additional categories which reflect the continuum of cognitive decline and impairment in populations we see that the 
mildest dementia declines, but that there is stability in estimates of those who meet MCI criteria. Increases were found in 
the Other Cognitive Impairment no Dementia group. The decline observed in severe impairment thus seems to have resulted 
in larger proportions of the population in milder forms, seen alongside physical illnesses.
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Introduction
Mild cognitive impairment (MCI) represents an intermediate 
state of cognitive functioning between changes expected as 
a normal part of ageing and dementia [1]. MCI prevalence 
has been estimated to range between < 1 and 42% in older 
populations depending on the classification criteria used and 
setting (e.g. clinical vs. population based) [2–4]. Reported 
rates of progression of MCI to dementia have also varied 
and range from around 8–15% per year [2]. However, not 
all individuals with MCI experience decline; MCI has been 
shown to be a transient state, with some of the MCI popula-
tion at risk of progressing to dementia at a later stage while 
others possibly regain cognitive function [5–9].
Defining subclinical cognitive impairment is complex and 
challenging due to a lack of standardised diagnostic criteria. 
Although the MCI criteria developed by Petersen and col-
leagues are an attempt to standardise subclinical impairment, 
concerns have emerged that the criteria are too restrictive 
[10, 11]. Population based studies have repeatedly shown 
that definitions of cognitive decline which cover a broader 
range of dysfunction, such as other cognitive impairment no 
dementia (OCIND) are more prevalent than more restrictive 
definitions of MCI and also have a high progression rate 
to dementia [6, 12]. There is also disagreement about the 
cut points used to define deficits in cognitive performance 
needed to distinguish MCI from minimal or questionable 
dementia [13, 14]. The longstanding approach of exclud-
ing individuals with medical comorbidities has also been 
challenged, with evidence suggesting that excluding this 
group could result in insufficient or biased MCI diagnosis, 
especially for clinical trials, thus restricting generalizability 
of results [15]. Consensus criteria proposed by the Inter-
national Working Group on Mild Cognitive Impairment, 
in 2004, broadened the concept developed by Petersen and 
colleagues to include impairment in any cognitive domain 
as well as relax criteria focused on functional impairment 
[3]. In 2011, the National Institute on Aging and the Alz-
heimer’s Association (NIA-AA) refined the definition of 
MCI to account for possible aetiologies, including amnestic 
MCI (aMCI) and non-amnestic MCI (naMCI) thought to 
be associated with AD and vascular dementia, respectively 
[16]. In 2013 the new Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-V) was released and 
included the diagnosis of mild neurocognitive disorder, a 
pre-dementia state based on MCI criteria [17]. Few com-
munity based populations have investigated DSM-V mild 
neurocognitive disorder, however a prevalence of 20% (95% 
CI 17.8–23.0) was reported in the LIFE-Adult-Study [18]. 
This study also found a 98.6% diagnostic overlap between 
the DSM-V and consensus MCI criteria.
Cohort effects have been observed in dementia. Indeed, 
in high income countries such as USA and UK, in the last 
2 decades, it appears that risk of dementia is declining [19]. 
Whether cohort effects are seen in the prevalence of MCI 
and risk of progression to dementia is not known but has 
important public health implications (e.g. calculating popu-
lation burden of disease). Further, determining how best 
to identify individuals at high risk of dementia will have 
important implications for intervention trials (e.g. clinical 
trial recruitment protocols), treatment (e.g. personalised 
medicine), public health surveillance (e.g. monitoring) 
and education (e.g. prevention programmes). Therefore, in 
this study, MCI (defined using consensus criteria) [20], in 
addition to other states of the entire cognitive spectrum, are 
investigated in the Cognitive Function and Ageing Studies 
(CFAS) in order to determine whether similar trends are 
seen for these states in the last 2 decades as those seen in 
dementia.
Methods
Setting, study design, and participants
Information on the CFAS I and II study designs has been 
published in detail previously [21, 22]. In brief, CFAS I 
baseline interviews were undertaken between 1989 and 
1994. In total, 13,044 individuals aged 65 years and older 
were recruited in five geographical areas in England and 
Wales including: Cambridgeshire, Oxfordshire, Nottingham, 
Newcastle and Gwynedd. Between 2008 and 2011 a new 
cohort of individuals (N = 7796), aged 65 years and older 
were selected and interviewed from three of the original 
CFAS areas: Cambridgeshire, Newcastle, and Nottingham 
with the aim to provide contemporary evidence on dementia 
prevalence, incidence and risk factors. This study of preva-
lence includes all participants who underwent diagnostic 
assessment in CFAS I and CFAS II (Fig. 1).
Ethics
Fully informed written consent was sought, and when capac-
ity was impaired procedures complied with the UK Mental 
Capacity Act 2005. Full details of ethical approvals in place 
for CFAS I and II can be found at: http://www.cfas.ac.uk/
cfas-i/data/#cfasi -ethic al-appro val.
Outcome description
Full details of the cognitive outcomes are described in the 
Appendix. Briefly we sought to classify the entire cognitive 
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spectrum of the older population from normal cognition, 
through mild cognitive impairment to dementia. Those with-
out study diagnosis of dementia were classified into groups: 
No cognitive impairment, MCI, other cognitive impairment 
not dementia (OCIND—with and without functional impair-
ment) and cognitive impairment with (mild dementia) and 
without functional impairment (Supplementary Table 1, 
Fig. 2).
Statistical analysis
Prevalence estimates were obtained using a multinomial 
logistic regression model, which predicted the probability 
of participants belonging to each group within the cogni-
tive spectrum in one model. Participants with no cogni-
tive impairment were treated as the reference group. This 
was repeated for men and women in each 5-year age band. 
Predicted probabilities were multiplied by UK population, 
Fig. 1  CFAS I and CFAS II 
study design
Fig. 2  Flow chart describing diagnostic criteria for definitions of 
cognitive spectrum. Dementia diagnosed using GMS AGECAT 
diagnosis—DSM-III-R, subjective memory complaint was meas-
ured through informant or proxy interview for evidence of memory 
impairment or decline over 6  months. Global cognitive impairment 
was measured using the Mini Mental State Examination (MMSE) 
with impairment established by scoring below 24, domain specific 
impairment was measured using the CAMCOG examination, and 
impairment was defined as ≤ 16th percentile using education adjusted 
percentile regression modelling. Disability (FI) was defined as hav-
ing impairments in BADL’s. Amnestic, non-amnestic and multiple 
domain MCI was established using memory and non-memory com-
ponents of the CAMCOG, for this analysis Revised MCI criteria was 
defined by having aMCI, naMCI or mMCI
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stratified by age and sex to estimate population prevalence 
[22]. Inverse probability weights were used to adjust for 
non-response (CFAS I and CFAS II) and screen-assessment 
sampling (CFAS I), based on UK age, sex and deprivation 
structure. The three centres (Cambridgeshire, Newcastle 
and Nottingham) included in both CFAS I (n = 7635) and 
II (n = 7796) were used. Bootstrap resampling with 1000 
replications was used to calculate 95% confidence intervals 
(95% CI) via the [bias corrected and accelerated] percentile 
method.
Age and sex specific prevalence estimates were combined 
with population data to obtain the number of individuals 
in the population in each cognitive group in 1991 (using 
CFAS I estimates) and in 2011 (using CFAS II estimates) 
[23]. Predicted estimates of the population assuming a con-
stant prevalence over the 2 decades was calculated using the 
CFAS I estimates combined with the 2011 UK population 
data.
Results
Sample demographics
In CFAS I 7635 individuals took part in the baseline wave 
(80% response), with 1459 taking part in the wave 1 assess-
ment interview (82% of those still alive), giving an overall 
response rate of 66% to the assessment interview. In CFAS 
II screen and assessment was undertaken in one stage and 
had a response rate of 56%. Figure 1 shows the number of 
individuals included in the baseline interviews in CFAS I 
and II. Demographic characteristics including age, sex, loca-
tion, education, baseline cognitive function, Basic Activities 
of Daily Living/Instrumental Activities of Daily Living and 
dementia status are shown in Table 1.
UK population prevalence of each cognitive group
Figure 3 shows the prevalence of each cognitive group 
standardized to the age and sex structure of the UK in 
1991 and 2011. The figure also shows the estimated 
prevalence for 2011 from age and sex-based predictions 
from the 1991 data. Cohort effects were observed in the 
definitions of mild dementia and cognitive impairment. 
Over the 2 decades, mild dementia has almost halved 
from 520,704 cases (5.7%, 95% CI 3.8, 8.1) in 1991 to 
315,142 cases (3.0%, 95% CI 2.4, 3.8) in 2011 (Table 2). 
There has been a larger decrease in cognitive impairment, 
which has proportionally fallen by more than half from 
1,225,984 (13.5%, 95% CI 10.1, 17.5) to 654,436 cases 
(6.3%, 95% CI 5.4, 7.3) (Table 2). This contrasts with 
the age-based projections which predicted that the preva-
lence of mild dementia and cognitive impairment would 
have remained relatively stable at 6.2% (95% CI 4.1, 8.7) 
and 13.4% (95% CI 9.9, 17.5), respectively (Table 2). 
The reduction in MCI prevalence over the 2 decades was 
small (2.4%) suggesting stable case numbers: 1,590,481 
cases (17.6%, 95% CI 12.5, 22.9) versus 1,575,577 cases 
(15.2%, 95% CI 13.8, 16.6). In contrast between 1991 
and 2011, OCIND (without FI) prevalence increased from 
3,331,809 (36.8%, 95% CI 30.3, 43.6) to 4,191,265 cases 
(40.4%, 95% CI 38.5, 42.3) while prevalence of OCIND 
(with FI) remained stable (5.0%, 95% CI 2.6, 8.1 in 1991 
vs. 5.6%, 95% CI 4.6, 6.5 in 2011) (Table 2). The numbers 
of people with no cognitive impairment increased from 
1,291,396 cases (14.3%, 95% CI 9.3, 19.4) in 1991, to an 
estimated 2,376,070 cases (22.9%, 95% CI 21.3, 24.5), 
this result was also higher than the predicted age-based 
Table 1  Baseline sociodemographic characteristics of CFAS I and II
Characteristics (n (%)) including sex, age group, education (years 
full time), geographical area, residential status and dementia status. 
Percentages are backed weighted for initial non-response (CFAS I 
screening and CFAS II) and study design (CFAS I assessment)
Data are n (%)
CFAS, Cognitive Function and Ageing Study
a Percentages back-weighted for non-response
b Percentages back-weighted for sampling design and non-response
c Residential status missing for seven individuals for CFAS I (of 
whom five were also assessed)
CFAS I CFAS II
Screening (%)a Assessment (%)b N (%)c
Sex
Men 3045 (39) 531 (38) 3550 (44)
Women 4590 (61) 926 (62) 4246 (56)
Age group
65–69 1981 (25) 310 (23) 1939 (23)
70–74 1776 (23) 320 (22) 1874 (23)
75–79 1725 (22) 263 (23) 1623 (21)
80–84 1308 (18) 291 (20) 1289 (17)
85–89 615 (9) 186 (9) 769 (11)
> 90 230 (4) 87 (3) 302 (6)
Education (years full time)
0–9 5529 (74) 1074 (80) 1976 (26)
10 644 (9) 106 (8) 2734 (36)
> 10 1286 (17) 172 (12) 2909 (38)
Geographical area
Cambridgeshire 2601 (34) 465 (37) 2558 (30)
Newcastle 2522 (33) 499 (31) 2616 (34)
Nottingham 2512 (33) 493 (32) 2622 (35)
Residential status
Community 7281 (95) 1269 (95) 7599 (97)
Care homes 347 (5) 183 (5) 197 (3)
Dementia NA 329 (8.6) 461 (6)
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projections for 2011 of 1,518,700 cases (14.6%, 95% CI 
9.6, 19.9). 
Discussion
Using CFAS I and II the prevalence of the full spectrum 
of cognitive function including normal, MCI, OCIND and 
dementia (including its mildest forms) could be measured 
over 2 decades with population resampling. There is clear 
evidence of a cohort effect in the prevalence of mild demen-
tia (decrease), cognitive impairment (decrease) and OCIND 
without functional impairment (increased). The numbers of 
people with no impairment have also increased relative to 
the age-based projections for 2011. Cohort effects are not 
seen in MCI and OCIND (with functional impairment), 
the prevalence of which appear to remain stable over the 
2 decades.
There are a number of strengths to the study. This study is 
able to investigate cognitive impairment across the full spec-
trum (i.e. from no impairment to dementia), strengthened by 
the methodological approach of using repeated prevalence’s 
studies. CFAS give unique insight based on random sam-
pling from three areas of England, allowing the examination 
of cross-generational cognitive impairment, being powered 
to detect changes and implementation of consistent meth-
ods and diagnostic procedures. There are also some limita-
tions. First, although the key methodologies of CFAS I and 
II are identical, CFAS I comprised a two-stage design with 
the complete cognitive assessment on a subsample, though 
the analysis does take this fully into account. CFAS II was 
designed to avoid this complexity while retaining the ability 
to compare results across the two studies. Second, dementia 
was diagnosed algorithmically using the AGECAT validated 
with DSM-III-R. With the introduction of new DSM-V cri-
teria, it is unknown whether prevalence of dementia or MCI 
may have differed had these criteria been applied. Under-
standing population change in MCI has been complicated by 
the lack of standardised cut-off scores, age norms, changing 
criteria including DSM-V creating an unstable environment. 
The advantage of using population based data is that it was 
collected without applying criteria and can be used to opera-
tionalise criteria that were not developed at the time of the 
study. Here we used consensus criteria for MCI which has 
been shown that when compared with the recent DSM-V 
criteria of mild neurocognitive disorder has high diagnostic 
overlap (98.6%) [17, 20].
While cohort effects were observed across the spectrum 
of cognitive impairment there were differences depend-
ing on group. Cognitive impairment and mild dementia 
do not share the same level of decrease as has been pre-
viously observed in dementia with both groups seeing a 
far greater reduction. When we combine the estimates of 
dementia, mild dementia and cognitive impairment in the 
older population together it corresponds to over one mil-
lion people in 2018 with many likely to have very similar 
care needs to those with a diagnosis of dementia. In con-
trast, the proportion of cases with no cognitive impairment 
and OCIND (without FI) increased. A possible explana-
tion for this is that the trends in population ageing along 
with improvements in education, health care and reduc-
tion of cardiovascular risk factors associated with cogni-
tive impairment have led to a greater proportion of older 
people with no impairment. Further, where cognition has 
declined it remains mild rather than declining to the point 
of impairment. Interestingly the prevalence of MCI has 
remained stable since 1991. The estimated prevalence is 
consistent with other large cohort studies internationally, 
with the average prevalence of MCI from consensus crite-
ria around 12% and 18% [24–28].
There is much debate in the literature about the variance 
in MCI prevalence estimates from epidemiological studies 
[2]. Evidence suggests that lack of consistency is largely due 
to a lack of standardised diagnostic criteria and homogenous 
study designs, methodology and populations [20]. For dec-
ades, the main area of disagreement has been around how 
Table 2  Prevalence of cognitive impairment standardized to UK population age and sex structure
Estimates were obtained using multiple regression modelling, with 95% CI’s obtained by bootstrap with 1000 replications via the percentile 
method. Age based projections for 2011 were obtained using 1991 estimates applied to 2011 population
Cognitive group CFAS I 2011 Age based projections CFAS II
n % (95% CI) n % (95% CI) n % (95% CI)
NCI 1,291,396 14.3 (9.3, 19.4) 1,518,700 14.6 (9.6, 19.9) 2,376,070 22.9 (21.3, 24.5)
OCIND 3,331,809 36.8 (30.3, 43.6) 3,695,737 35.6 (29.2, 42.5) 4,191,265 40.4 (38.5, 42.3)
MCI 1,590,481 17.6 (12.5, 22.9) 1,775,397 17.1 (12.1, 22.4) 1,575,577 15.2 (13.5, 16.6)
OCIND (with FI) 456,253 5.0 (2.6, 8.1) 522,149 5.0 (2.6, 8.1) 577,559 5.6 (4.6, 6.5)
Cognitive impairment 1,225,984 13.5 (10.1, 17.5) 1,395,954 13.4 (9.9, 17.5) 654,436 6.3 (5.4, 7.3)
Mild dementia 520,704 5.7 (3.8, 8.1) 638,522 6.2 (4.1, 8.7) 315,142 3.0 (2.4, 3.8)
Dementia 642,238 7.1 (5.3, 9.2) 833,426 8.0 (6.1, 10.4) 690,051 6.6 (5.6, 7.8)
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to define mild impairment by neuropsychological testing; 
for example, tighter definitions such as scoring 1.5 stand-
ard deviations from normal on memory domain tests show 
much lower prevalence’s compared to the DSM-V criteria 
of between 1 and 2 standard deviations on non-specified 
domain testing [4]. Recently the criteria for MCI has nar-
rowed with the introduction of consensus criteria [20] and 
different subtypes (amnestic MCI, non-amnestic MCI and 
multiple MCI) with the aim to help improve diagnostic accu-
racy [2]. Consensus criteria were selected for this study, for 
reasons stated earlier, and different changes over time may 
be obtained if a different definition were used. But this is 
beyond the scope of the current study.
The results show that since 1991 there has been a shift in 
the cognitive burden within the older population; although 
the prevalence of dementia and its mild dementia forms may 
be declining, OCIND is increasing and MCI is stable. These 
results have a number of implications for strategic planning 
for cognitive impairment and dementia. First, they provide 
further evidence alongside studies [29–31] that have found 
a decline in risk of cognitive impairment (measured using 
CIND) in older aged populations; extending the findings 
for the first time by showing that although severe cognitive 
impairment and the mildest forms of dementia have decreased, 
mild impairment in the form of OCIND has increased and 
MCI has remained stable. Strategic planning for the numbers 
Fig. 3  Prevalence of cognitive 
impairment standardized to UK 
population age and sex structure 
(%). Estimates were obtained 
using multiple regression 
modelling, age based projec-
tions for 2011 were obtained 
using 1991 estimates applied 
to 2011 population. NCI, no 
cognitive impairment, OCIND, 
other cognitive impairment no 
dementia, MCI, mild cogni-
tive impairment, FI, functional 
impairment
CFAS I  - 1991 Age based projecons CFAS II - 2011
No Impairment 14.3% 14.6% 22.9%
OCIND 36.8% 35.6% 40.4%
MCI 17.6% 17.1% 15.2%
OCIND (with FI) 5.0% 5.0% 5.6%
Cognive Impairment 13.5% 13.4% 6.3%
Mild demena 5.7% 6.2% 3.0%
Demena 7.1% 8.0% 6.6%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NCI = No cognitive impairment, OCIND = Other Cognitive Impairment no Dementia, MCI = 
Mild Cognitive Impairment, FI=Functional impairment.  
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of people with dementia will have to be adjusted to budget 
correctly as the prevalence of the disease declines, however, 
this analysis shows that despite these trends, there is still a 
significant number of people with cognitive impairment and 
mild dementia who may indeed be missed from formal demen-
tia diagnosis but who have similar care needs. Planning for 
increasing numbers of people with OCIND and MCI is more 
complex, evidence suggests patients diagnosed with MCI 
prefer to undergo testing to predict dementia prevalence in 
the future; due to ever changing technologies, guidelines for 
diagnosis and management for MCI means testing is likely to 
be uncertain [32]. Diagnostic testing for MCI can incur heavy 
financial costs, and so far interventions to prevent or delay 
progression to dementia have limited efficacy [33, 34]. Plan-
ning for the future must involve policy makers and clinicians 
discussing the balance of risks and benefits of interventions, 
also involving patient’s views on interventions in later life.
In addition, our results suggest that changes seen in the 
population that has prevented dementia, has also impacted on 
severe cognitive impairment. However, what is not clear is 
whether lifestyle factors such as education and improved car-
diovascular and metabolic health is having the same reductive 
effect on MCI [30, 35]. Indeed, the findings suggest that the 
increase in OCIND and stability of MCI could reflect “normal 
cognitive ageing” among a population which is substantially 
older. As well as the financial burden, a diagnosis of MCI can 
lead to emotional distress and social stigma; cognitive decline 
is a subject of fear among older people and patients may thus 
prefer foregoing the diagnosis altogether [33, 36]. In light of 
this care must be taken not to wrongly identify people with 
MCI as a clinical condition, which may be “normal cognitive 
ageing”. Clinical decision making regarding MCI will likely 
change in light of an effective disease modifying agent for 
pre-dementia being identified. In the meantime evidence sug-
gests it is through healthy lifestyle behaviours, better educa-
tional attainment, minimizing risks from polypharmacy and 
comorbidities in the wider population which should be further 
encouraged to reduce risk of severe cognitive impairment [30].
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